All News Omni Bio Pharmaceutical, Inc.

Equities

OMBP

US68216L1008

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+66.67%	+233.33%

2016	Omni Bio Pharmaceutical, Inc. cancelled the transaction announced on March 16, 2015	CI
2015	Omni Bio Pharmaceutical, Inc. Announces Management Changes	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Omni Bio Pharmaceutical, Inc. cancelled the transaction announced on March 16, 2015	15/03/16	CI
Omni Bio Pharmaceutical, Inc. Announces Management Changes	25/06/15	CI
Omni Bio Pharmaceutical, Inc. announced a financing transaction	15/03/15	CI
Omni Bio Pharmaceutical, Inc. announced that it has received $2.3 million in funding from Bohemian Investments	12/03/15	CI
Omni Bio Pharmaceutical, Inc. Announces Clinical Data for Use of Alpha-1 Antitrypsin in Steroid-Resistant Graft Versus Host Disease	09/12/14	CI
Omni Bio Pharmaceutical, Inc. Announces Presentation of Phase 1/2 Clinical Data for AAT at American Heart Association Scientific Sessions	19/11/14	CI
Omni Bio Successfully Completes Cell Line Optimization for Novel Recombinant Biologic	18/11/14	CI
Omni Bio Pharmaceutical, Inc. Appoints Jack Riccardi as Chief Financial Officer, with Effect from September 1, 2014	14/08/14	CI
Omni Bio Pharmaceutical, Inc. Auditor Raises 'Going Concern' Doubt	15/06/14	CI
Omni Bio Pharmaceutical, Inc. Appoints Bruce D. Forrest as Chief Development Officer	01/05/14	CI
Omni Bio Pharmaceutical, Inc. Announces Publication of Its Pilot Study of Alpha-1 Antitrypsin in Type 1 Diabetes	30/04/14	CI
Gallus BioPharmaceuticals, LLC Enters Cell Line Optimization and Manufacturing Agreement with Omni Bio Pharmaceutical, Inc	29/04/14	CI
Omni Bio Pharmaceutical, Inc. announced that it expects to receive $2 million in funding from Bohemian Investments.	14/04/14	CI
Robert C. Ogden Tenders Resignation as Chief Financial Officer of Omni Bio Pharmaceutical, Inc., Effective March 28, 2014	07/03/14	CI
Omni Bio Pharmaceutical, Inc. Receives Notice of Allowance for the Use of Alpha-1 Antitrypsin to Reduce Risk of Non-Organ Transplant Rejection and to Treat Graft Versus Host Disease	26/11/13	CI
Omni Bio Pharmaceutical, Inc. Announces Reduction in Inflammatory Myocardial Injury with its Lead Recombinant Molecule	20/11/13	CI
Omni Bio Pharmaceutical, Inc. Receives Notice of Allowance for its First U.S. Patent Action for Recombinant Alpha-1 Antitrypsin Molecule	06/11/13	CI
Omni Bio Pharmaceutical, Inc. Announces Board Changes	15/08/13	CI
Omni Bio Pharmaceutical, Inc. Appoints Sandra J. Wrobel to its Board of Directors	17/07/13	CI
Omni Bio Pharmaceutical, Inc. Announces Resignation of Michael Iseman as Member of the Board of Directors	11/07/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Omni Bio Pharmaceutical, Inc.

Equities

OMBP

US68216L1008

All News

Filters